A technology best known for transforming vaccine development is now reaching a major milestone in cancer research. After years of work on treatments designed around the unique characteristics of individual tumors,

Scientists said the drug trial of the treatment for melanoma could be the beginning of a transformation in care.

Adding the cancer vaccine intismeran autogene to pembrolizumab (Keytruda) significantly improved recurrence-free survival and distant metastasis-free survival in a phase III trial of completely resected melanoma, Merck and Moderna announced.

Doctors break down what you need to know.

The combined drug works by nudging the body's own immune system to make proteins that attack and destroy melanoma cells